Chen YC, Li CY, Tsai SJ, Chen YC. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World J Clin Cases 2019; 7(11): 1270-1281 [PMID: 31236391 DOI: 10.12998/wjcc.v7.i11.1270]
Corresponding Author of This Article
Yi-Chun Chen, MD, Assistant Professor, Doctor, Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Minsheng Rd., Dalin Township, Chiayi County 622, Taiwan. chenyichun0320@yahoo.com.tw
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 4 Sensitivity analysis of adjusted hazard ratios for end-stage renal disease and death between the untreated and uninfected chronic kidney disease patients as well as between the treated and untreated chronic kidney disease patients